SCHEMBL1408708

SCHEMBL1408708

C[C@@H](NS(=O)(=O)CCCOCn1ccc(=O)[nH]c1=O)c1cccc(OCC2CC2)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
DUT P33316 20/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1408710 1.00 DUT (1.00) DUT
SCHEMBL1409662 0.97 DUT (1.00) DUT
SCHEMBL1409663 0.97 DUT (1.00) DUT
SCHEMBL1409443 0.93 DUT (1.00) DUT
SCHEMBL1409486 0.92 DUT (1.00) DUT
SCHEMBL1409484 0.92 DUT (1.00) DUT
SCHEMBL1409765 0.92 DUT (1.00) DUT
SCHEMBL1409746 0.92 DUT (1.00) DUT
SCHEMBL1409928 0.92 DUT (1.00) DUT
SCHEMBL1409750 0.92 DUT (1.00) DUT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2508185-B1 ANTI-TUMOR EFFECT POTENTIATOR TAIHO PHARMACEUTICAL CO LTD (JP) 2020-03-04 EP claimed
US-8883759-B2 Anti-tumor effect potentiator TAIHO PHARMACEUTICAL CO., LTD. (JP) 2014-11-11 US claimed
US-8530490-B2 Uracil compound or salt thereof having human deoxyuridine triphosphatase inhibitory activity TAIHO PHARMACEUTICAL CO., LTD. (JP) 2013-09-10 US claimed
EP-2295414-B1 URACIL COMPOUND HAVING INHIBITORY ACTIVITY ON HUMAN DEOXYURIDINE TRIPHOSPHATASE OR SALT THEREOF TAIHO PHARMACEUTICAL CO LTD (JP) 2012-09-26 EP claimed
US-20120225838-A1 ANTI-TUMOR EFFECT POTENTIATOR TAIHO PHARMACEUTICAL CO., LTD. (JP) 2012-09-06 US claimed
US-20110082163-A1 NOVEL URACIL COMPOUND OR SALT THEREOF HAVING HUMAN DEOXYURIDINE TRIPHOSPHATASE INHIBITORY ACTIVITY TAIHO PHARMACEUTICAL CO., LTD. (JP) 2011-04-07 US claimed
EP-2295414-A1 NOVEL URACIL COMPOUND HAVING INHIBITORY ACTIVITY ON HUMAN DEOXYURIDINE TRIPHOSPHATASE OR SALT THEREOF Taiho Pharmaceutical Co., Ltd. (JP) 2011-03-16 EP claimed
US-11247984-B2 Uracil containing compounds CV6 THERAPEUTICS (NI) LIMITED (GB) 2022-02-15 US disclosed
EP-3673908-B1 ANTI-TUMOR EFFECT POTENTIATOR TAIHO PHARMACEUTICAL CO LTD (JP) 2022-01-12 EP disclosed
EP-3673908-B1 ANTI-TUMOR EFFECT POTENTIATOR TAIHO PHARMACEUTICAL CO LTD (JP) 2022-01-12 EP disclosed
EP-3673908-A1 ANTI-TUMOR EFFECT POTENTIATOR Taiho Pharmaceutical Co., Ltd. (JP) 2020-07-01 EP disclosed
EP-2508185-B1 ANTI-TUMOR EFFECT POTENTIATOR TAIHO PHARMACEUTICAL CO LTD (JP) 2020-03-04 EP disclosed
EP-2508185-B1 ANTI-TUMOR EFFECT POTENTIATOR TAIHO PHARMACEUTICAL CO LTD (JP) 2020-03-04 EP disclosed
US-20120225838-A1 ANTI-TUMOR EFFECT POTENTIATOR TAIHO PHARMACEUTICAL CO., LTD. (JP) 2012-09-06 US disclosed
WO-2011065541-A1 ANTI-TUMOR EFFECT POTENTIATOR 大鵬薬品工業株式会社 (JP) 2011-06-03 WO disclosed
US-20110082163-A1 NOVEL URACIL COMPOUND OR SALT THEREOF HAVING HUMAN DEOXYURIDINE TRIPHOSPHATASE INHIBITORY ACTIVITY TAIHO PHARMACEUTICAL CO., LTD. (JP) 2011-04-07 US disclosed
US-20110082163-A1 NOVEL URACIL COMPOUND OR SALT THEREOF HAVING HUMAN DEOXYURIDINE TRIPHOSPHATASE INHIBITORY ACTIVITY TAIHO PHARMACEUTICAL CO., LTD. (JP) 2011-04-07 US disclosed
EP-2295414-A1 NOVEL URACIL COMPOUND HAVING INHIBITORY ACTIVITY ON HUMAN DEOXYURIDINE TRIPHOSPHATASE OR SALT THEREOF Taiho Pharmaceutical Co., Ltd. (JP) 2011-03-16 EP disclosed
EP-2295414-A1 NOVEL URACIL COMPOUND HAVING INHIBITORY ACTIVITY ON HUMAN DEOXYURIDINE TRIPHOSPHATASE OR SALT THEREOF Taiho Pharmaceutical Co., Ltd. (JP) 2011-03-16 EP disclosed
WO-2009147843-A1 NOVEL URACIL COMPOUND HAVING INHIBITORY ACTIVITY ON HUMAN DEOXYURIDINE TRIPHOSPHATASE OR SALT THEREOF 大鵬薬品工業株式会社 (JP) 2009-12-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120225838-A1 ANTI-TUMOR EFFECT POTENTIATOR CCNT1, CCNA1, UPP1 DUT 305/4885
US-11247984-B2 Uracil containing compounds UNG, DPYD, DUT DUT 3/4885
US-20110082163-A1 NOVEL URACIL COMPOUND OR SALT THEREOF HAVING HUMAN DEOXYURIDINE TRIPHOSPHATASE INHIBITORY ACTIVITY SNRPB2, SNRPA1, DUT DUT 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.